Table 1.

Biochemical and hormonal features of patient series at the onset of hypophysitis.

	Patient				Reference range
	1	2	3	4
Cancer type	NSCLC	NSCLC	Melanoma	Melanoma
ICI/dose	Atezolizumab (anti-PD-L1)	Nivolumab (anti-PD-1)	Pembrolizumab (anti-PD-1)	Nivolumab and ipilimumab*
ICI cycle	4	6	9	1
Sodium, mEq/L	121	121	132	131	135–145
Potassium, mEq/L	7.9	4.1	3.6	4.5	3.5–5.1
Glucose, mg/dL	180#	108	117	145#	74–109
Cortisol, mcg/dL	<0.4	3	0.4	0.8	6.7–22.6
ACTH, ng/L	4	<5	<5	5	<50
Renin, mIU/mL	350.6	38		36	4.4–46.1
FSH, mIU/mL	1.1	0,4	10	9.3	1.3–19.5
LH, mIU/mL	1.3	<0,2		5.1	1.4–12.7
Testosterone, µg/L	1.9	<0,1	2,2	–	1.75–7.8
Estradiol, ng/mL	–	–	–	140	>20
PRL, ng/mL	11	4,2	19	14	M: 2–13; F: 2–25
IGF-1, µg/L	157	78	85	123	58–212
FT4, ng/dL	1.2	0.85	0.95#	0.92#	0.7–1.7
TSH, µIU/mL	0.7	0.9	8#	5#	0.4–4
TgAb, IU/mL	Negative	Negative	504	7	<30
TPOAb, IU/mL	Negative	Negative	769	85	<10
21-Hydroxylase Ab, IU/mL	89.3	Negative	Negative	Negative	<0.40
Anti-pituitary Ab	Positive			Positive	Negative
Anti-GAD Ab, IU/mL	<1	<1	<1	<1	<1
Anti-IA2 Ab	<1	<1	<1	<1	<1 IU/mL
HLA haplotypes	DRB1*04; DQB1*03	–	–	DQB1*02; DQB1 *0602; DQA1 *0102

^#During L-thyroxine therapy, #during insulin therapy. *Ipilimumab was given after six cycles of Nivolumab.

ICI, immune checkpoint inhibitors.